Research Cart
Your cart is empty
Add research compounds to get started.
Incretin Agonist Comparison
Single. Dual. Triple.
A side-by-side scientific comparison of three generations of incretin-based peptide research compounds — from GLP-1 monotherapy to the novel triple receptor agonist Retatrutide.
Semaglutide1st Generation
Tirzepatide2nd Generation
Retatrutide3rd Generation
1st GenerationView Semaglutide
Semaglutide
GLP-1 Receptor Agonist
GLP-1
GIP
GCG
Mean Body Weight Reduction~15%
vs. placebo in Phase 2/3 trials
Molecular Weight4,113.6 g/mol
Half-Life~7 days
Purity99%+
Research Pricing
2mg
$49.99
5mg
$99.99
10mg
$179.99
2nd GenerationView Tirzepatide
Tirzepatide
Dual GIP / GLP-1 Agonist
GLP-1
GIP
GCG
Mean Body Weight Reduction~21%
vs. placebo in Phase 2/3 trials
Molecular Weight4,813.5 g/mol
Half-Life~5 days
Purity99%+
Research Pricing
2mg
$59.99
5mg
$119.99
10mg
$199.99
3rd GenerationView Retatrutide
Retatrutide
Triple GIP / GLP-1 / GCG Agonist
GLP-1
GIP
GCG
Mean Body Weight Reduction~24%
vs. placebo in Phase 2/3 trials
Molecular Weight4,731.4 g/mol
Half-Life~6 days
Purity99%+
Research Pricing
2mg
$69.99
5mg
$149.99
10mg
$269.99
Side-by-Side Comparison
Receptor targets and molecular profile at a glance
| Parameter | Semaglutide GLP-1 Receptor Agonist | Tirzepatide Dual GIP / GLP-1 Agonist | Retatrutide Triple GIP / GLP-1 / GCG Agonist |
|---|---|---|---|
| Mechanism | |||
GLP-1 Receptor Glucagon-Like Peptide-1 receptor — primary target for appetite suppression and insulin secretion | Active | Active | Active |
GIP Receptor Glucose-Dependent Insulinotropic Polypeptide receptor — enhances insulin secretion and may improve tolerability | None | Active | Active |
Glucagon Receptor Glucagon receptor — drives hepatic glucose output and increases energy expenditure | None | None | Active |
| Molecular Profile | |||
Molecular Weight | 4,113.6 g/mol | 4,813.5 g/mol | 4,731.4 g/mol |
Half-Life | ~7 days | ~5 days | ~6 days |
Purity | 99%+ | 99%+ | 99%+ |
Semaglutide
Extensively studied with large Phase 3 trial data
Well-characterized safety and tolerability profile
Longest clinical track record of the three
Single receptor target — predictable mechanism
Lower weight reduction vs. dual/triple agonists
No direct GIP or glucagon receptor activity
Limited effect on energy expenditure vs. glucagon agonism
Tirzepatide
Superior weight reduction vs. semaglutide in head-to-head trials
Dual receptor mechanism offers additive metabolic benefits
Robust Phase 3 clinical trial dataset
GIP activity may improve tolerability profile
No glucagon receptor activity (no direct energy expenditure boost)
Newer compound with less long-term follow-up vs. semaglutide
Higher molecular complexity vs. single agonists
Retatrutide
Highest observed weight reduction of any incretin compound in research
Unique glucagon receptor activity increases energy expenditure
Triple mechanism offers broadest metabolic coverage
Active Phase 3 trials — most novel compound in the class
Newest compound — Phase 2 data only (Phase 3 ongoing)
Glucagon activity requires careful study of hepatic effects
Less long-term safety data vs. semaglutide and tirzepatide